A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer
| Autor: | Garry Alan Weems, H. Jeffrey Wilkins, Melissa Lynne Johnson, Shirish M. Gadgeel, D. Ross Camidge |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Orphan receptor Agonist Cancer Research medicine.drug_class business.industry Retinoic acid Pembrolizumab medicine.disease 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Immune system Oncology chemistry 030220 oncology & carcinogenesis medicine Cancer research Biomarker (medicine) In patient Lung cancer business |
| Zdroj: | Journal of Clinical Oncology. 36:TPS9111-TPS9111 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | TPS9111Background: LYC-55716 is a first-in-class oral, small-molecule agonist of the retinoic acid receptor–related orphan receptor γ (RORγ) being developed as an immuno-oncology agent for solid tu... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|